Supplementation of Eriocitrin in Intestinal Microbiota

Effect of Chronic Eriocitrin Supplementation on the Intestinal Microbiota of Pre-diabetic and Insulin Resistant Individuals

Sponsors

Lead Sponsor: São Paulo State University

Source São Paulo State University
Brief Summary

Pre-diabetes is characterized by high plasma concentration of glucose and glycated hemoglobin and is the main risk factor for the development of type 2 diabetes. Several studies show that the intestinal microbiota is intimately linked to cardio-metabolic factors (type 2 diabetes, insulin resistance) when in situations of dysbiosis. Food is a key element for a healthy microbiota, focusing on the consumption of polyphenols that modulate the intestinal environment through its alteration and production of short chain fatty acids, and can thus be a way of reversing situations such as pre- diabetes and insulin resistance. The objective of the study will be to investigate whether chronic supplementation of eriocitrin alters the intestinal microbiota of pre-diabetic and insulin resistant individuals, reversing these situations. This will be done by supplementation of eriocitrin-containing capsules with different dosages in pre-diabetic and insulin resistant individuals. There will be 12 weeks of intervention, with faecal collections, anthropometric and dietary evaluation, and then will be made microbiological analysis to identify the intestinal microbiota and biochemical analysis before and after the intervention. For statistical analysis, normality and homogeneity test (Kolmogorov-Smirnov and Levine test respectively), T-test to compare baseline time between groups and repeated-measures ANOVA (two-way) were used to compare changes within and between groups.

Detailed Description

Individuals of both sexes between 30 and 60 years of age who present fasting glycemia between 100 mg / dL (5,6 mmol / L) and 125 mg / dL (6,9 mmol / L) 50, or concentration of glycated hemoglobin between 5.7% (39 mmol / mole) and 6.4% (47 mmol / mole) 50, or glycemic concentrations in the oral glucose tolerance test between 140mg / dL (7.8 mmol / L) to 199mg / dL (11.0 mmol / L) 50. The study will also include insulin-resistant individuals: insulin above 25 uU / mL, or who present HOMA-IR score above 2.7.

Individuals using supplements (vitamins, bioflavonoids), pregnant women and those who practice intense physical exercise (> 10h / week) will be excluded from the study.

The primary endpoint will be alteration of the microbiota with possible improvement of the glycemic profile, leading to the reversal of pre-diabetes and insulin resistance.

Overall Status Terminated
Start Date May 1, 2019
Completion Date March 23, 2020
Primary Completion Date August 1, 2019
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Rate of change in microbiome 0-12 week
Secondary Outcome
Measure Time Frame
Rate of change in plasma glucose concentration 0-12 week
Enrollment 40
Condition
Intervention

Intervention Type: Dietary Supplement

Intervention Name: Eriocitrin

Description: The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.

Eligibility

Criteria:

Inclusion Criteria:

- 30-60 years

- Increased fasting blood glucose from 6.1 to 7.0 mmol / L or,

- Decreased glucose tolerance of 7 , 8 to 11.1 mmol / L or,

- Glycated hemoglobin with values between 5.7 and 6.4%

Exclusion Criteria:

- Use hypoglycemic, hypolipidemic drugs,

- Use dietary supplements (vitamins, minerals, bioflavonoids, prebiotics, probiotics or other bioactive compounds),

- Exercise intensely (more than 10 hours per week)

- History of cardiovascular diseases , diabetes mellitus, liver and kidney disease.

Gender: All

Minimum Age: 30 Years

Maximum Age: 60 Years

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Thais B Cesar, Phd Principal Investigator ao Paulo State University "Julio de Mesquita Filho"
Location
Facility: Sao Paulo State University "Julio de Mesquita Filho"
Location Countries

Brazil

Verification Date

March 2020

Responsible Party

Type: Principal Investigator

Investigator Affiliation: São Paulo State University

Investigator Full Name: Thais Cesar

Investigator Title: Principal Investigator

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 4
Arm Group

Label: Eriomin 200 mg

Type: Experimental

Description: The volunteers will receive one capsule containing 200 mg eriocitrin

Label: Eriomin 400 mg

Type: Experimental

Description: The volunteers will receive one capsule containing 400 mg eriocitrin

Label: Eriomin 800 mg

Type: Experimental

Description: The volunteers will receive one capsule containing 800 mg eriocitrin

Label: Placebo

Type: No Intervention

Description: The volunteers will receive a capsule containing corn starch (placebo)

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Triple (Participant, Investigator, Outcomes Assessor)

Source: ClinicalTrials.gov